None listed
Conditions
Brief summary
This observational study is collecting information from patients to form the Myeloma and Related Diseases Registry (MRDR) Who is it for? You may be eligible for this study if you have a diagnosis of multiple myeloma, plasmacytoma, plasma cell leukaemia or monoclonal gammopathy of undetermined significance (MGUS). Study details Medical information including diagnostic tests, therapy and demographics will be provided by medical records. Participants can also provide information regarding their quality of life using a questionnaire. It is hoped this registry will enable clinicians and hospitals to provide the best possible care to people with the included conditions and allow the evaluations of new therapies.
Interventions
The Myeloma and Related Diseases Registry (MRDR) is an ongoing register of patients with a new diagnosis of multiple myeloma, plasmacytoma, plasma cell leukaemia or monoclonal gammopathy of undetermined significance (MGUS). The MRDR was established in 2012 in Australia and New Zealand. In 2018, the MRDR expanded to the Asia-pacific region and includes patients from Korea, Singapore, China/ Taiwan, and Malaysia.
Sponsors
Monash University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients with a new diagnosis of multiple myeloma, plasmacytoma, plasma cell leukaemia or monoclonal gammopathy of undetermined significance (MGUS). Diagnosis within 3 months prior to HREC approval at a site for myeloma, plasmacytoma, plasma cell leukaemia and within 5 years for MGUS in order to minimise retrospective data collection.
Exclusion criteria
People who decline to participate in the registry.
Outcome results
None listed